

IMMUNOLOGY

PHASE I	PHASE II	PHASE III	APPROVED INDICATIONS
TYK2 Inhibitor (2) --Autoimmune Disease TLR 7/8 Antagonist --Autoimmune Disease S1P1 Agonist --Autoimmune Disease IL-2 Agonist --Autoimmune Disease MK2 --Autoimmune Disease	Branebrutinib --Rheumatoid Arthritis --Sjögren's Disease --Systemic Lupus Erythematosus TYK2 Inhibitor --Crohn's Disease --Lupus Nephritis --Psoriatic Arthritis --Systemic Lupus Erythematosus --Ulcerative Colitis Iberdomide(CELMoD) --Systemic Lupus Erythematosus Anti-IL-13 --Eosinophilic Esophagitis	ORENCIA --Idiopathic Inflammatory Myopathy NULOJIX --Switch from Calcineurin Inhibitor Renal Transplant TYK2 Inhibitor --Psoriasis Ozanimod --Crohn's Disease --Relapsing Multiple Sclerosis --Ulcerative Colitis	ORENCIA --Active Polyarticular JIA --Early Rheumatoid Arthritis --JIA Intravenous --JIA Subcutaneous --Psoriatic Arthritis --RA Auto injector --RA Intravenous --RA Subcutaneous NULOJIX --De Novo Renal Transplant

CARDIOVASCULAR

PHASE I	PHASE II	PHASE III	APPROVED INDICATIONS
Factor XIa Inhibitor^a (2) --Thrombotic Disorders FPR-2 Agonist --Heart Failure Relaxin --Heart Failure	ELIQUIS^a --Pediatric Heart Disease Nitroxyl Donor --Heart Failure Factor XIa Inhibitor^a --Thrombotic Disorders		ELIQUIS^a --Stroke Prevention in Atrial Fibrillation --Venous Thromboembolism Prevention Orthopedic Surgery --Venous Thromboembolism Treatment

FIBROTIC DISEASES

PHASE I	PHASE II
LPA₁ Antagonist --Pulmonary Fibrosis	HSP47^a --Fibrosis Pegbelfermin --Non-alcoholic Steatohepatitis JNK Inhibitor --Idiopathic Pulmonary Fibrosis --Non-Alcoholic Steatohepatitis

Note: Above pipeline excludes clinical collaborations

^a Development Partnership: **OPDIVO, YERVOY, Relatlimab, EP4**: Ono (our collaboration with Ono also includes other early stage compounds); **EMPLICITI**: AbbVie; **Bempegaldesleukin**: Nektar; **Cabiralizumab**: Five Prime Therapeutics, Inc.; **Cabozantinib**: Exelixis, Inc.; **ELIQUIS**: Pfizer; **Factor XIa Inhibitor**: Janssen Pharmaceuticals, Inc.; **HSP47**: Nitto Denko Corporation; **CD3XCD33**, **GEMoAB CD3xPSCA**, **GEM333**: GeMoaB Monoclonals GmbH; **bb21217**, **ide-cel**: bluebird bio, Inc.; **REBLOZYL**: Acceleron Pharma Inc.; **IDHIFA**, **MAT2A**: Agios Pharmaceuticals, Inc.; **AHR**: Ikena Oncology

^ Trial(s) exploring various combinations

Partner-run study